Galmed Pharmaceuticals (NASDAQ: GLMD) and Applied Genetic Technologies Corporation (NASDAQ:AGTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitabiliy and institutional ownership.
This table compares Galmed Pharmaceuticals and Applied Genetic Technologies Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Applied Genetic Technologies Corporation||17.61%||6.62%||4.49%|
Volatility and Risk
Galmed Pharmaceuticals has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies Corporation has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.
Insider & Institutional Ownership
8.0% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 61.5% of Applied Genetic Technologies Corporation shares are held by institutional investors. 2.5% of Applied Genetic Technologies Corporation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Galmed Pharmaceuticals and Applied Genetic Technologies Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Galmed Pharmaceuticals||$735,000.00||115.72||-$15.85 million||($1.39)||-5.03|
|Applied Genetic Technologies Corporation||$43.24 million||2.17||$8.04 million||$0.41||12.68|
Applied Genetic Technologies Corporation has higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Applied Genetic Technologies Corporation, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for Galmed Pharmaceuticals and Applied Genetic Technologies Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Applied Genetic Technologies Corporation||0||3||6||0||2.67|
Galmed Pharmaceuticals presently has a consensus price target of $11.75, indicating a potential upside of 68.10%. Applied Genetic Technologies Corporation has a consensus price target of $14.63, indicating a potential upside of 181.25%. Given Applied Genetic Technologies Corporation’s higher possible upside, analysts plainly believe Applied Genetic Technologies Corporation is more favorable than Galmed Pharmaceuticals.
Applied Genetic Technologies Corporation beats Galmed Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Applied Genetic Technologies Corporation Company Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.